Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.

[1]  A. Puren,et al.  Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa , 2019, AIDS.

[2]  L. Myer,et al.  Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study) , 2019, PLoS medicine.

[3]  S. Lockman,et al.  Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. , 2019, The New England journal of medicine.

[4]  R. Walensky,et al.  Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential , 2019, Annals of Internal Medicine.

[5]  M. Penazzato,et al.  Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  A. Wensing,et al.  Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study , 2018, The lancet. HIV.

[7]  B. Sartorius,et al.  Investigating risk factors for under-five mortality in an HIV hyper-endemic area of rural South Africa, from 2000-2014 , 2018, PloS one.

[8]  L. Mofenson.  In-utero ART exposure and the need for pharmacovigilance. , 2018, The Lancet. Global health.

[9]  E. Barr,et al.  Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV , 2018, AIDS.

[10]  A. Medina-Marino,et al.  Determinants of late antenatal care presentation in rural and peri-urban communities in South Africa: A cross-sectional study , 2018, PloS one.

[11]  D. Moodley,et al.  Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE) A Randomized, Open-Label, Clinical Trial , 2017, Journal of acquired immune deficiency syndromes.

[12]  Tulio de Oliveira,et al.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis , 2017, The Lancet. Infectious diseases.

[13]  K. Maitland,et al.  Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa , 2017, The New England journal of medicine.

[14]  L. Myer,et al.  HIV viraemia and mother‐to‐child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa , 2017, HIV medicine.

[15]  Wendy Watson,et al.  Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data , 2016, Vaccine.

[16]  Qingling Chen,et al.  Early Initiation of ARV During Pregnancy to Move towards Virtual Elimination of Mother-to-Child-Transmission of HIV-1 in Yunnan, China , 2015, PloS one.

[17]  L. Myer,et al.  Plasma viraemia in HIV-positive pregnant women entering antenatal care in South Africa , 2015, Journal of the International AIDS Society.

[18]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[19]  M. Pirmohamed,et al.  Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool , 2011, PloS one.

[20]  P. Reiss,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. , 2008, The Lancet. Infectious diseases.

[21]  Dart Trial Team.  Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/μl , 2008 .

[22]  P. Price,et al.  Immune restoration disease after antiretroviral therapy , 2004, AIDS.

[23]  Emmanuel M. Kaijuka.  Uganda demographic and health survey , 1989 .